ReviewCurrent diabetes reports2021
Value of Patient-Centered Glycemic Control in Patients with Type 2 Diabetes.
Review in Current diabetes reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- The EQ-5D-5L index as a measure of health-related quality of life in type 2 diabetes: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Pooled it
- Bioequivalence assessment of imeglimin hydrochloride tablet, a novel glimin-class antidiabetic agent.Naunyn-Schmiedeberg's archives of pharmacology · 2026Trial
- National Survey on Implementation Patterns and Functional Needs for Hospital-Wide Glycemic Management Systems in the Chinese Mainland: Mixed Methods Study.Journal of medical Internet research · 2026Article
- Anti-diabetic potential of Artemisia monosperma Delile extract related to anti-inflammatory, antioxidant, and wound-healing properties.Scientific reports · 2026Article
- Hepatogenous diabetes in the era of precision medicine: diagnosis, management, and future directions.Clinical and experimental medicine · 2026Review
- Comparison of Clinical Outcomes between Newly Diagnosed and Pre-Existing Diabetes Mellitus Patients after Acute Coronary Syndrome.Current vascular pharmacology · 2026Article
- In Pursuit of Person-Centered Medicine: How Do People with Type 2 Diabetes Choose Glucose-Lowering Medications? A Qualitative Study.Journal of general internal medicine · 2026Article
- Initial treatment for uncontrolled type 2 diabetes: A clinical trial comparing basal insulin and modified-release gliclazide.Caspian journal of internal medicine · 2026Article
- Medical Management of Coronary Artery Disease: An Update.The International journal of angiology : official publication of the International College of Angiology, Inc · 2025Review
- Recognizing the Role of Insulin Resistance in Polycystic Ovary Syndrome: A Paradigm Shift from a Glucose-Centric Approach to an Insulin-Centric Model.Journal of clinical medicine · 2025Review
- Perspectives on Stringent Glycemic Control and Weight Loss Among Patients with Type 2 Diabetes in China: A Survey Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Exploring the impact of self-efficacy on glycemic control in Omani type 2 diabetes patients.Frontiers in endocrinology · 2025Article
- Independent and joint associations of sleep quality and physical activity with glycaemic control in patients with type 2 diabetes mellitus.Frontiers in nutrition · 2025Article
- The association between alcohol drinking and glycemic management among people with type 2 diabetes in China.Journal of diabetes investigation · 2024Article
- Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials.The review of diabetic studies : RDS · 2023Review
- Advances in the management of type 2 diabetes in adults.BMJ medicine · 2023Review
- Antidiabetic activity ofFrontiers in nutrition · 2022Article
- Glycemic control and its influencing factors in type 2 diabetes patients in Anhui, China.Frontiers in public health · 2022Article
- Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.Diabetes & vascular disease researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewPresent the value of a person-centered approach in diabetes management and review current evidence supporting its practice. RECENT
findingsEarly evidence from glycemic control trials in diabetes resulted in most practice guidelines adopting a glucose-centric intensive approach for management of the disease, consistently relying on HbA1c as a marker of metabolic control and success. This paradigm has been recently dispelled by new evidence that shows that intensive glycemic control does not provide a significant benefit regarding patient-important microvascular and macrovascular hard outcomes when compared to moderate glycemic targets. The goals of diabetes therapy are to reduce the risks of acute and chronic complications and increase quality of life while incurring least burden of treatment and disruption to the patient's life. A person-centered approach to diabetes management is achieved through shared decision making, integration of evidence-based care and patient´s needs, values and preferences, and minimally disruptive approaches to diabetes care and at the same time offer practical guidance to clinicians and patients on achieving this type of care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.